| acute myocardial infarction | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ESPRIM, 1994 | molsidomine vs placebo | | | deaths at 2 days 0.76 [0.52; 1.12] early death 1.03 [0.81; 1.31] | | Beaufils, 1988 | molsidomine vs placebo | | | early death 0.56 [0.21; 1.48] |
| Trial | Treatments | Patients | Method |
|---|
| ESPRIM, 1994 | linsidomine 1 mg/h intravenously for 48 h, followed by 16 mg molsidomine by mouth daily for 12 days (n=2007) vs. placebo (n=2010) | patients with acute myocardial infarction within 24 h of symptom onset | double blind Parallel groups Sample size: 2007/2010 Primary endpoint: FU duration: 13 mo | | Beaufils, 1988 | molsidomine for 10 days (n=133) vs. placebo (n=137) | patients with a first myocardial infarction within 6 hours from onset of symptoms | double blind Parallel groups Sample size: 133/137 Primary endpoint: FU duration: 10 days |
|
